Cyp3a Inhibitors (Moderate And Strong) has 4 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Bedaquiline Fumarate, Amlodipine And Valsartan, Tovorafenib. Patients taking Cyp3a Inhibitors (Moderate And Strong) should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 4
- Contraindicated
- 1
- Moderate
- 3
Contraindicated (1)
- Cyp3a Inhibitors (Moderate And Strong) + Bedaquiline Fumarate— Coadministration may decrease systemic exposure of bedaquiline. Avoid use of strong and moderate CYP3A4 inducers with SI…
Moderate (3)
- Cyp3a Inhibitors (Moderate And Strong) + Amlodipine And Valsartan— Coadministration results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for hypote…
- Cyp3a Inhibitors (Moderate And Strong) + Tovorafenib— CYP2C8 inhibitors are predicted to increase tovorafenib exposure, which may increase the risk of adverse reactions. Avoi…
- Cyp3a Inhibitors (Moderate And Strong) + Valsartan And Hydrochlorothiazide— Coadministration with CYP3A inhibitors increases systemic exposure to amlodipine and may require dose reduction. Monitor…